124 related articles for article (PubMed ID: 31569304)
21. Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606.
Mancini M; Brusa G; Zuffa E; Corrado P; Martinelli G; Grafone T; Barbieri E; Santucci MA
Leuk Res; 2007 Jul; 31(7):979-87. PubMed ID: 17129604
[TBL] [Abstract][Full Text] [Related]
22. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.
Jallal H; Valentino ML; Chen G; Boschelli F; Ali S; Rabbani SA
Cancer Res; 2007 Feb; 67(4):1580-8. PubMed ID: 17308097
[TBL] [Abstract][Full Text] [Related]
23. Anti-survivin effect of the small molecule inhibitor YM155 in RCC cells is mediated by time-dependent inhibition of the NF-κB pathway.
Sim MY; Yuen JSP; Go ML
Sci Rep; 2018 Jul; 8(1):10289. PubMed ID: 29980758
[TBL] [Abstract][Full Text] [Related]
24. A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects.
Abbas R; Hug BA; Leister C; Sonnichsen D
Int J Cancer; 2012 Aug; 131(3):E304-11. PubMed ID: 22065400
[TBL] [Abstract][Full Text] [Related]
25. SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer.
Kim WG; Guigon CJ; Fozzatti L; Park JW; Lu C; Willingham MC; Cheng SY
Clin Cancer Res; 2012 Mar; 18(5):1281-90. PubMed ID: 22271876
[TBL] [Abstract][Full Text] [Related]
26. The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases.
Ozanne J; Prescott AR; Clark K
Biochem J; 2015 Jan; 465(2):271-9. PubMed ID: 25351958
[TBL] [Abstract][Full Text] [Related]
27. Neutrophil FcγRIIA promotes IgG-mediated glomerular neutrophil capture via Abl/Src kinases.
Nishi H; Furuhashi K; Cullere X; Saggu G; Miller MJ; Chen Y; Rosetti F; Hamilton SL; Yang L; Pittman SP; Liao J; Herter JM; Berry JC; DeAngelo DJ; Zhu C; Tsokos GC; Mayadas TN
J Clin Invest; 2017 Oct; 127(10):3810-3826. PubMed ID: 28891817
[TBL] [Abstract][Full Text] [Related]
28. Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.
Homsi J; Cubitt CL; Zhang S; Munster PN; Yu H; Sullivan DM; Jove R; Messina JL; Daud AI
Melanoma Res; 2009 Jun; 19(3):167-75. PubMed ID: 19434004
[TBL] [Abstract][Full Text] [Related]
29. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity.
Lai SW; Bamodu OA; Tsai WC; Chang YM; Lee WH; Yeh CT; Chao TY
Clin Exp Metastasis; 2018 Oct; 35(7):663-677. PubMed ID: 29987671
[TBL] [Abstract][Full Text] [Related]
30. Src family kinase inhibitor bosutinib enhances retinoic acid-induced differentiation of HL-60 leukemia cells.
MacDonald RJ; Bunaciu RP; Ip V; Dai D; Tran D; Varner JD; Yen A
Leuk Lymphoma; 2018 Dec; 59(12):2941-2951. PubMed ID: 29569971
[TBL] [Abstract][Full Text] [Related]
31. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
Golas JM; Arndt K; Etienne C; Lucas J; Nardin D; Gibbons J; Frost P; Ye F; Boschelli DH; Boschelli F
Cancer Res; 2003 Jan; 63(2):375-81. PubMed ID: 12543790
[TBL] [Abstract][Full Text] [Related]
32. Bosutinib Stimulates Macrophage Survival, Phagocytosis, and Intracellular Killing of Bacteria.
da Silva RAG; Stocks CJ; Hu G; Kline KA; Chen J
ACS Infect Dis; 2024 May; 10(5):1725-1738. PubMed ID: 38602352
[TBL] [Abstract][Full Text] [Related]
33. Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib.
Redaelli S; Boschelli F; Perini P; Pirola A; Viltadi M; Gambacorti-Passerini C
Leukemia; 2010 Jun; 24(6):1223-7. PubMed ID: 20445575
[No Abstract] [Full Text] [Related]
34. Bosutinib reduces the efficacy of Dasatinib in triple-negative breast cancer cell lines.
Tarpley M; Abdissa TT; Johnson GL; Scott JE
Anticancer Res; 2014 Apr; 34(4):1629-35. PubMed ID: 24692691
[TBL] [Abstract][Full Text] [Related]
35. Bosutinib: a novel second-generation tyrosine kinase inhibitor.
Isfort S; Keller-v Amsberg G; Schafhausen P; Koschmieder S; Brümmendorf TH
Recent Results Cancer Res; 2014; 201():81-97. PubMed ID: 24756786
[TBL] [Abstract][Full Text] [Related]
36. Bosutinib: a third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Hill BG; Kota VK; Khoury HJ
Expert Rev Anticancer Ther; 2014 Jul; 14(7):765-70. PubMed ID: 24875651
[TBL] [Abstract][Full Text] [Related]
37. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models.
Golas JM; Lucas J; Etienne C; Golas J; Discafani C; Sridharan L; Boghaert E; Arndt K; Ye F; Boschelli DH; Li F; Titsch C; Huselton C; Chaudhary I; Boschelli F
Cancer Res; 2005 Jun; 65(12):5358-64. PubMed ID: 15958584
[TBL] [Abstract][Full Text] [Related]
38. Anti-proliferative effect of RCE-4 from Reineckia carnea on human cervical cancer HeLa cells by inhibiting the PI3K/Akt/mTOR signaling pathway and NF-κB activation.
Bai C; Yang X; Zou K; He H; Wang J; Qin H; Yu X; Liu C; Zheng J; Cheng F; Chen J
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):573-84. PubMed ID: 26935715
[TBL] [Abstract][Full Text] [Related]
39. Micro-osmotic pumps for continuous release of the tyrosine kinase inhibitor bosutinib in juvenile rats and its impact on bone growth.
Tauer JT; Hofbauer LC; Jung R; Erben RG; Suttorp M
Med Sci Monit Basic Res; 2013 Nov; 19():274-8. PubMed ID: 24185529
[TBL] [Abstract][Full Text] [Related]
40. Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.
Nguyen T; Hawkins E; Kolluri A; Kmieciak M; Park H; Lin H; Grant S
Leuk Res; 2015 Jan; 39(1):65-71. PubMed ID: 25465126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
